Natco Pharma (NSE:NATCOPHARM) Other Current Receivables: ₹98 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
92 GF Score
Price ₹907.00
GF Value ₹1,043.40
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Other Current Receivables?

Natco Pharma NSE:NATCOPHARM -0.38% 92 Other Current Receivables is ₹98 Mil as of Mar. 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 92/100 and a GF Value™ of ₹1,043.40 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Natco Pharma's Other Current Receivables for the quarter that ended in Mar. 2026 was ₹98 Mil.

Natco Pharma's quarterly Other Current Receivables declined from Sep. 2025 (₹102.00 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹98.00 Mil).

Natco Pharma's annual Other Current Receivables increased from Mar. 2024 (₹796.00 Mil) to Mar. 2025 (₹1,139.00 Mil) but then declined from Mar. 2025 (₹1,139.00 Mil) to Mar. 2026 (₹98.00 Mil).

Natco Pharma Other Current Receivables Related Terms

Natco Pharma Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Natco Pharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma Other Current Receivables Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 649.00 453.00 796.00 1,139.00 98.00

Natco Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,139.00 0.00 102.00 0.00 98.00
NSE:NATCOPHARM
92GF Score
Natco Pharma Ltd NSE:NATCOPHARM
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹98 Mil mean?
Natco Pharma (NSE:NATCOPHARM) has a Other Current Receivables of ₹98 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Natco Pharma and its competitors.
Is Natco Pharma's Other Current Receivables too high?
Natco Pharma's current Other Current Receivables is ₹98 Mil. Overall, Natco Pharma has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Other Current Receivables compare to ZTS?
Natco Pharma's Other Current Receivables of ₹98 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Natco Pharma and its competitors. Natco Pharma's current Other Current Receivables is ₹98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,043.40, compared to a current price of ₹907.00 — trading 13.1% below its estimated fair value. The current Other Current Receivables is ₹98 Mil. Natco Pharma's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Other Current Receivables is ₹98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued. The current stock price of ₹907.00 is trading 13.1% below its estimated GF Value™ of ₹1,043.40. GuruFocus considers Natco Pharma to be Modestly Undervalued.

Key valuation signals for NSE:NATCOPHARM:

  • Other Current Receivables: ₹98 Mil
  • GF Value™: ₹1,043.40 vs. price of ₹907.00 (13.1% below fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
92GF Score

Get the complete analysis for NSE:NATCOPHARM

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹907.00
Price
₹1,043.40
GF Value